On the stock market since 2022, it operates in the world of health and science. It has 217 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 39% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 3 years, sales grew about 45% a year on average.
Sales run at $272.3M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 13 buys and 11 sells. Management buying with its own money is usually read as a good sign.
A loss of $5.1M against $272.3M in annual sales.
On our five-subject report card, HROWM sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: HROWM is a high-risk stock — not yet profitable, and its future rides on its product catching on.